- 作者: Li-Ju Lai; Xiao Xiao; June H. Wu
- 作者服務機構: 1 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Kwei San, Tao Yuan, 333, Taiwan; ; 2 Department of Ophthalmology, Chang Gung Memorial Hospital, 199 Tung-Hwa North Road, Taipei, 105, Taiwan; ; 3 Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA, 15213, USA; ; 4 Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Kwei San, Tao Yuan, 333, Taiwan e-mail: jhwu@mail.cgu.edu. tw
- 中文摘要: --
- 英文摘要: The use of a recombinant adeno-associated viral (rAAV) vector carrying endostatin gene as an anti-angiogenesis strategy to treat corneal neovascularization in a mouse model was evaluated. Subconjunctival injection of recombinant endostatin-AAV was used to examine the inhibition of corneal neovascularization induced by silver nitrate cauterization in mice. The results showed that gene expression in corneal tissue was observed as early as 4 days after gene transfer and stably lasted for over 8 months with minimal immune reaction. Subconjunctival injection of a high-titer rAAV-endostatin successfully inhibited neovascularization. Tmmunohistchemistry staining of CD 31 and endostatin showed that the treatment significantly inhibits angiogenesis in cornea. We concluded that the rAAV was capable of directly delivering genes to the ocular surface epithelium by way of subconjunctival injection and was able to deliver sustained, high levels of gene expression in vivo to inhibit angiogenesis.
- 中文關鍵字: --
- 英文關鍵字: adeno-associated viral (AAV) vector, angiogenesis, corneal neovascularization, endostatin gene, gene therapy, ocular surface disease